Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product R&D

Enter GammaDelta

How GammaDelta's T cells could become the newest cancer immunotherapy class

Lauren Martz, Senior Writer
September 15, 2016 7:00 AM UTC
Lauren Martz, Senior Writer

Today's launch of Abingworth-backed GammaDelta Therapeutics Ltd. could signal the rise of γδ T cells as the newest class of cancer immunotherapies. The company is the second founded in as many years to capitalize on the small subclass that Abingworth believes could outstrip the more common αβ T cells filling company pipelines.

Abingworth will incubate GammaDelta in its London offices and is providing an undisclosed amount of seed funding...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article